World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
95
Citations
31967
World Ranking
10098
National Ranking
5201

Gregory H. Reaman publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Gregory H. Reaman sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 369 publications — 32nd percentile

32% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Gregory H. Reaman D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Gregory H. Reaman sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 95 D-Index — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Gregory H. Reaman is affiliated with the US Food and Drug Administration in the United States. Their research primarily spans the field of Medicine, with significant contributions to Pediatrics, Perinatology and Child Health, Public Health, Environmental and Occupational Health, Oncology, Neurology, and Molecular Biology.

The scientist's work addresses various specialized topics including:

  • Childhood Cancer Survivors' Quality of Life
  • Pharmaceutical studies and practices
  • Acute Lymphoblastic Leukemia research
  • Neuroblastoma Research and Treatments
  • CAR-T cell therapy research
  • Ethics and Legal Issues in Pediatric Healthcare
  • Statistical Methods in Clinical Trials

Frequently collaborating with other researchers, their notable co-authors include Dominik Karres, Gilles Vassal, Andrew D.J. Pearson, Malcolm A. Smith, and Nicole Scobie, each having contributed in multiple joint publications.

Gregory H. Reaman has published extensively in leading journals, with frequent appearances in:

  • European Journal of Cancer
  • Journal of Clinical Oncology
  • Pediatric Blood & Cancer
  • JNCI Journal of the National Cancer Institute
  • Clinical Pharmacology & Therapeutics

Their selected recent papers represent a focus on pediatric oncology and drug development, including:

  • FDA Approval Summary: Selumetinib for Plexiform Neurofibroma, 2021, Clinical Cancer Research
  • ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients, 2020, European Journal of Cancer
  • Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies, 2021, European Journal of Cancer
  • ACCELERATE - Five years accelerating cancer drug development for children and adolescents, 2022, European Journal of Cancer
  • Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents, 2020, European Journal of Cancer

In addition to journal articles, Gregory H. Reaman has contributed to book publications, including the 2022 title Pediatric Cancer Therapeutics Development published by Springer International Publishing.

Best Publications

  • Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.

    Charles G Mullighan;Xiaoping Su;Jinghui Zhang;Ina Radtke

  • Outcomes for Children and Adolescents With Cancer: Challenges for the Twenty-First Century

    Malcolm A. Smith;Nita L. Seibel;Sean F. Altekruse;Lynn A.G. Ries

  • Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group

    Stephen P. Hunger;Xiaomin Lu;Meenakshi Devidas;Bruce M. Camitta

  • Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia

    Kathryn G. Roberts;Ryan D. Morin;Jinghui Zhang;Martin Hirst

  • High Risk of Subsequent Neoplasms Continues With Extended Follow-Up of Childhood Hodgkin’s Disease: Report From the Late Effects Study Group

    Smita Bhatia;Yutaka Yasui;Leslie L. Robison;Jillian M. Birch

  • Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia

    Richard C. Harvey;Richard C. Harvey;Charles G. Mullighan;I-Ming Chen;I-Ming Chen;Walker Wharton

  • JAK mutations in high-risk childhood acute lymphoblastic leukemia.

    Charles G. Mullighan;Jinghui Zhang;Richard C. Harvey;J. Racquel Collins-Underwood

  • Declining childhood and adolescent cancer mortality.

    Malcolm A. Smith;Sean F. Altekruse;Peter C. Adamson;Gregory H. Reaman

  • Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome.

    Richard C. Harvey;Richard C. Harvey;Charles G. Mullighan;Xuefei Wang;Kevin K. Dobbin

  • American Society of Clinical Oncology Statement: Achieving High-Quality Cancer Survivorship Care

    Mary S. McCabe;Smita Bhatia;Kevin C. Oeffinger;Gregory H. Reaman

  • Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis.

    Donald A. Berry;Shouhao Zhou;Howard Higley;Lata Mukundan

  • Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood

    R J Packer;B Lange;J Ater;H S Nicholson

  • Recombinant Urate Oxidase for the Prophylaxis or Treatment of Hyperuricemia in Patients With Leukemia or Lymphoma

    Ching-Hon Pui;Hazem H. Mahmoud;Joseph M. Wiley;Gerald M. Woods

  • Phase II Study of Nelarabine (compound 506U78) in Children and Young Adults With Refractory T-Cell Malignancies: A Report From the Children’s Oncology Group

    Stacey L. Berg;Susan M. Blaney;Meenakshi Devidas;Tom A. Lampkin

  • Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group.

    Joanne M. Hilden;Patricia A. Dinndorf;Sharon O. Meerbaum;Harland Sather

  • Progress in Childhood Cancer: 50 Years of Research Collaboration, A Report from the Children's Oncology Group

    Maura O'Leary;Mark Krailo;James R. Anderson;Gregory H. Reaman

  • Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.

    Jinghui Zhang;Charles G. Mullighan;Richard C. Harvey;Gang Wu

  • The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA

    Philipp Kapranov;Georges St Laurent;Georges St Laurent;Tal Raz;Fatih Ozsolak

  • Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and out come prediction in pedeatric b-precursor acute lymphoblastic leukemia

    Cheryl L. Willman;Richard Harvey;Huining Kang;Edward Bedrick

  • Early Response to Therapy and Outcome in Childhood Acute Lymphoblastic Leukemia A Review

    Paul S. Gaynon;Anish A. Desai;Bruce C. Bostrom;Raymond J. Hutchinson

Frequent Co-Authors

Paul S. Gaynon
Paul S. Gaynon University of Southern California
Harland N. Sather
Harland N. Sather University of Southern California
David G. Poplack
David G. Poplack Baylor College of Medicine
Ching-Hon Pui
Ching-Hon Pui St. Jude Children's Research Hospital
Diane C. Arthur
Diane C. Arthur National Institutes of Health
Paul A. Bunn
Paul A. Bunn University of Colorado Boulder
Mark E. Nesbit
Mark E. Nesbit University of Minnesota
Mike Clarke
Mike Clarke Queen's University Belfast
Stephen E. Sallan
Stephen E. Sallan Harvard University
John H. Kersey
John H. Kersey University of Minnesota

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens the door to a range of related health and science careers. Today, flexible online programs make it easier than ever to pursue these paths while balancing work and personal commitments.

For those interested in promoting health and wellness, an online bachelor's in nutrition can lead to diverse roles in healthcare, counseling, or food science. If your ambitions are in healthcare leadership, cahme accredited online mha programs offer rigorous training in administration and management, fully online and widely respected in the industry.

Nurses seeking to upgrade credentials may consider the best online rn to bsn programs without clinical requirements, which provide a convenient pathway to advancement without in-person practicum. For experienced nurses aiming for the highest clinical roles, a 1 year dnp program online offers expedited, doctoral-level training that can dramatically enhance career opportunities.

Each of these online programs offers flexibility, streamlined coursework, and targeted expertise, helping you position yourself for a rewarding career in healthcare or allied fields.

Best Scientists Citing Gregory H. Reaman

Trending Scientists

Recently Published Articles